Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors are indebted to Angela Pries and Christina Beutel who performed SLAMF7 analysis by flow cytometry of the Department of Hematology, AK St. Georg, Hamburg, Germany. We also thank J. H. Butterfield (Mayo Clinic, Rochester, MN, USA) for providing HMC-1.2 cells.

Author contributions

AE and MH have written the paper. HS, CJ, AS, FD, and YS have contributed data of patients. MV and CN has performed the IHC with SLAMF7. MH has provided fundamental material.

Disclosure statement

No potential conflict of interest was reported by the authors.